1 completed, 1 unknown. 1 Not applicable, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Unknown 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow Teijin Pharma Limited: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized Placebo-controlled Multicenter Trial to Evaluate the Efficacy and Safety of JTR-161, Allogeneic Human Dental Pulp Stem Cell, in Patients With Acute Ischemic stRoke (J-REPAIR) JTR-161, Placebo - Acute Ischemic Stroke | Phase 1 / Phase 2 | Completed | Teijin Pharma Limited | 79 | 2019-01-30 | 2022-06-30 |
| Febuxostat for Cerebral and caRdiorenovascular Events prEvEntion stuDy Febuxostat - Hyperuricemia | Not applicable | Unknown | Freed Study Group | 1000 | 2013-11-01 | 2016-08-26 |
Hyperuricemia (1) · Ischemic Stroke (1)
Febuxostat (1)
Japan (2)
Hisao Ogawa (1)
PMID 27005768, PMID 30844048, PMID 34605897, PMID 35613802, PMID 35648242, PMID 38389505